Based on a large-scale nationwide screening platform—the SCRUM-Japan GI-SCREEN and the GOZILA networks—we designed TRIUMPH, a phase 2 trial to evaluate the efficacy of pertuzumab plus trastuzumab in patients with mCRC with RAS wild-type and HER2 amplification prospectively confirmed by tumor tissue or ctDNA analysis. The gene discussed is ERBB2; the disease is neoplasm.